NEW & HOT

Lucid and Bolt Partner to Deploy 25,000 Autonomous Electric Vehicles Across Europe EPA Formally Finalizes Repeal of Power Plant Carbon Capture and Greenhouse Gas Mandates Congress Overwhelmingly Passes Landmark Bipartisan Sanctions Targeting Shadow Fleet Oil Networks AI Leaders Urge Coordinated Pacing and Independent Safety Audits for Frontier Models Global Oil Prices Surpass $100 as Saudi Pipeline Outage Constrains Supply Rare Palm-Sized Fen Raft Spider Population Rebounds to Record Highs Across UK Nature Reserves International FlyWire Consortium Maps Complete 140,000-Neuron Connectome of Adult Fruit Fly Brain FDA Approves Pfizer's Hympavzi as First Once-Weekly Subcutaneous Treatment for Hemophilia A and B Lucid and Bolt Partner to Deploy 25,000 Autonomous Electric Vehicles Across Europe EPA Formally Finalizes Repeal of Power Plant Carbon Capture and Greenhouse Gas Mandates Congress Overwhelmingly Passes Landmark Bipartisan Sanctions Targeting Shadow Fleet Oil Networks AI Leaders Urge Coordinated Pacing and Independent Safety Audits for Frontier Models Global Oil Prices Surpass $100 as Saudi Pipeline Outage Constrains Supply Rare Palm-Sized Fen Raft Spider Population Rebounds to Record Highs Across UK Nature Reserves International FlyWire Consortium Maps Complete 140,000-Neuron Connectome of Adult Fruit Fly Brain FDA Approves Pfizer's Hympavzi as First Once-Weekly Subcutaneous Treatment for Hemophilia A and B

Topic

#Pfizer

Healthcare professional demonstrating a subcutaneous auto-injector pen for once-weekly hemophilia prophylaxis treatment

health U.S. Food and Drug Administr...

FDA Approves Pfizer's Hympavzi as First Once-Weekly Subcutaneous Treatment for Hemophilia A and B

The U.S. Food and Drug Administration approved Pfizer's Hympavzi (marstacimab-hncq) for routine prophylaxis in patients aged 12 and older with hemophilia A or B without inhibitors, delivered via a once-weekly auto-injector pen.

Jerry Vasoya · 11 Oct 2026 · 3 min read